실적분석 2026년 8월 4일

Bruker ($BRKR) Q2 2026 Earnings Analysis — Adjusted EPS Beat, Revenue Miss, Shares Plunge After-Hours

Earnings Scorecard

Revenue: $838.5M (+5.2% YoY, vs. $854M consensus) ❌ Miss

EPS: Adjusted $0.49 (vs. $0.38 consensus; GAAP diluted loss of $0.41) ✅ Beat

Guidance: Reaffirmed (only currency and tax rate revised) — FY2026 revenue $3.54B–$3.57B, adjusted EPS $2.10–$2.15

Stock reaction: -11.37% after-hours ($57) — as of 08-04 21:06 KST

The Good

Adjusted earnings surprise: Adjusted EPS of $0.49 handily beat the $0.38 consensus

Margin expansion: Adjusted operating margin of 14.1%, sharply up from 9.0% a year ago

Order recovery: Scientific Instruments organic orders +10% YoY; book-to-bill above 1.0x

Bruker is a scientific instruments company selling life-science, analytical and diagnostic equipment, as well as semiconductor metrology solutions. Q2 2026 revenue came in at $838.5M, up 5.2% from $797.4M a year earlier, with organic growth of 2.8% (3.4% excluding tariff refunds). Top-line growth wasn't dramatic, but cost and profitability discipline stood out: adjusted operating income climbed to $118.5M from $72M YoY, and adjusted EPS jumped from $0.32 to $0.49.

By segment, Scientific Instruments (BSI) revenue was $767.3M (+4.7%, organic +2.3%), while Energy & Superconductivity (BEST) revenue was $74.2M (+11.9%, organic +8.9%). Management attributed strong orders for differentiated products to semiconductor equipment, energy research and biopharmaceutical markets, and read the 10% organic order growth in Scientific Instruments — pushing book-to-bill above 1.0x — as a positive signal for H2 revenue visibility.

The Not-So-Good

Revenue miss: $838.5M came in roughly 1.8% below the $854M consensus

Large impairment: $134.9M non-cash goodwill charge drove a GAAP operating loss and per-share loss

Demand disparity: US academic demand remains soft; FY organic revenue growth guided to a modest 1–2%

Earnings beat, but the top line fell short of market expectations. The $838.5M print trailed the $854M analyst consensus — a combination that, despite solid adjusted earnings, can make the growth story look weaker. On a GAAP basis, the quarter showed an operating loss of $65.3M and a net loss attributable to common shareholders of $62.9M (after $10.9M in preferred dividends), translating to a diluted loss per share of $0.41, largely reflecting the $134.9M non-cash goodwill impairment. Breaking out the total net loss and the common-shareholder portion, Bruker's corporate net loss was $52M, while the loss attributable to common shareholders was $62.9M.

Regional and end-market temperatures diverged. US academic demand stayed weak in Q2, while European and Chinese academic and government orders were strong, per management. The company's FY2026 organic revenue growth guidance of 1–2% matches a "gradual recovery" tone, but investors hoping for a rapid rebound may view it as conservative. H1 cumulative revenue of $1,661.9M (+3.9%) was actually down 0.8% on an organic basis, underscoring how much M&A and FX are still carrying the growth.

What Management Said

Management said the FY2026 guidance was adjusted only for currency and tax rates. The adjusted EPS range of $2.10–$2.15 was maintained (up 15–17% from $1.83 last year), and revenue was set at $3.54B–$3.57B (+3–4% YoY, +1–2% organic). The key tweak was trimming the FX tailwind on revenue translation from about 1.5% previously to about 0.5%, while incorporating a 27.5% adjusted tax rate. The EPS guidance includes roughly $0.10 (~5%) of FX headwind.

CEO Frank H. Laukien stressed that returning to organic revenue growth in Q2, combined with cost and profitability focus, drove margin and adjusted EPS gains. Strong orders in semiconductor, energy and biopharma boost confidence, but he also acknowledged that US academic demand remains soft — delivering a "selective recovery" message. Management expressed growing confidence in a market recovery and expects organic margin expansion and adjusted EPS growth not only this year but into 2027. The annual growth pace isn't large in absolute terms, but the margin and earnings tone is optimistic, leaving investors inclined to further scrutinize how H2 orders translate into actual revenue and when the US academic recovery will materialize.

Market Reaction and What to Watch

The after-hours plunge reflects a repricing of the "earnings beat but disappointing growth" combination. Adjusted EPS handily beat expectations, but revenue missed consensus, and with FY organic growth of just 1–2%, US academic weakness and a large goodwill impairment, confidence in a "quality recovery" has eroded. Order recovery and margin improvement are positives, but for now the top-line miss and conservative growth guidance are weighing more heavily.

Watch whether Q3 Scientific Instruments order growth actually converts into revenue and organic growth.

Check whether US academic and medical-research demand is past the bottom and showing recovery signs.

Monitor whether FY revenue and adjusted EPS guidance is maintained, and assess the impact of any further impairments or FX moves.